[A19-39] Dacomitinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V

Last updated 01.08.2019

Project no.:

Commission awarded on 29.04.2019 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:


Adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations

Result of dossier assessment:

Patients with L858R or Del19 mutations: Advantages in overall survival and individual side effects are offset by numerous disadvantages in several outcome categories. Other mutations: No data available. Added benefit not proven for either of both research questions.


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Federal Joint Committee (G-BA)

2019-10-17 A G-BA decision was published.

G-BA documents on this decision


Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form